Terminally Ill Mother Fights for Access to Life-Saving Drug

Sophie Blake, a 53-year-old mother from Brighton, is battling terminal breast cancer while advocating for access to a life-extending drug called Enhertu. Currently, women in England, Wales, and Northern Ireland with HER2-low stage 4 secondary breast cancer are being denied this treatment, which could provide them with crucial additional time to live.

Blake, diagnosed with incurable stage four breast cancer in May 2022, has experienced the loss of two close friends in recent weeks who could have benefited from the drug. One of her friends was a mother of a five-year-old son, intensifying the tragedy of the situation. “I have lost so many friends who desperately needed this treatment,” Blake stated. “It is devastating and frankly, utterly shameful.”

The drug, which is available in various countries, has been denied approval by the National Institute for Health and Care Excellence (NICE) for use on the National Health Service (NHS). Despite offering hope for an additional six months of life, it has been classified as not cost-effective. Blake highlighted the disparity, stating, “Women are dying prematurely because of this decision.”

Government Decision Sparks Outrage

Blake’s diagnosis has caused significant changes in her life, especially in her role as a mother to her 18-year-old daughter, Maya Nicholls-Blake. “It’s like having a ticking time bomb inside me. I live scan by scan,” she explained, expressing the constant anxiety she faces regarding her health. The absence of Enhertu, she argues, has deprived her and many women of hope.

NICE’s decision in 2024 to not recommend Enhertu was based on its assessment that the drug was not cost-effective. This has raised concerns among healthcare professionals and patients alike. Blake noted, “Our fear is that drug companies will no longer seek approvals from NICE for new treatments, knowing that the funding hasn’t increased in 20 years.”

The implications of NICE’s ruling have widespread consequences. Metastatic breast cancer, one of the leading causes of death among women aged 35 to 64, has seen its classification downgraded from ‘severe’ to ‘moderate severe’ without consultation from oncologists. This change has diverted funding away from necessary treatments, leaving patients feeling neglected and undervalued.

A Call for Change and Hope

Organizations like Breast Cancer Now are actively campaigning for changes in drug approval processes, with over 250,000 individuals signing a petition to support the cause. “Despite this, women continue to die,” Blake lamented. Her oncologist, who referred to Enhertu as a “wonder drug,” was shocked by its rejection, emphasizing the urgent need for reevaluation of the current system.

NICE expressed disappointment over the failure to reach a pricing agreement with the drug’s manufacturers, emphasizing that a fair price is essential for making medications available to those in need. “The fastest and only guaranteed way to get medicines like Enhertu to the patients who need them is for companies to offer a fair price,” a spokesperson stated.

The emotional toll on patients and their families is profound. Blake’s story serves as a stark reminder of the urgency for reform in drug accessibility and approval processes. “The precious time we have left living should be about making memories with our families, not fighting constantly for our lives,” she concluded, highlighting the need for compassion and understanding in healthcare decisions.